ITS' Flunisyn Elicits Strong T-Cell Response in Phase IIa

Moran, Nuala
April 2013
BioWorld International;4/17/2013, Vol. 18 Issue 16, p1
The article reports that biotechnology firm Immune Targeting Systems Ltd. (ITS) has released positive results on its universal influenza vaccine, Flunisyn. Phase IIa trial on Flunisyn showed that it induced T-cell responses in 95 percent of an elderly population. It also showed a good safety profile, and the cell-mediated immune response to Flunisyn did not inhibit antibody response to a conventional influenza vaccine.


Related Articles

  • Immune Targeting Raises $7.1M To Boost Its Vaccine Pipeline. Moran, Nuala // BioWorld International;7/18/2007, Vol. 12 Issue 29, p3 

    This article reports on the £3.5 million funds raised by Immune Targeting System Ltd. to finance the clinical trial of its universal influenza A vaccine. It says that the funding round was led by Novartis Venture Fund. Companies that invested into Immune Targeting System include Truffle...

  • The role of invariant natural killer T cells in dendritic cell licensing, cross-priming, and memory CD8+ T cell generation. Gottschalk, Catherine; Mettke, Elisabeth; Kurts, Christian // Frontiers in Immunology;Jul2015, p1 

    New vaccination strategies focus on achieving CD8+ T cell (CTL) immunity rather than on induction of protective antibody responses. While the requirement of CD4+ T (Th) cell help in dendritic cell (DC) activation and licensing, and in CTL memory induction has been described in several disease...

  • Bird flu vaccine may be within reach.  // Australian Nursing Journal;Apr2009, Vol. 16 Issue 9, p23 

    The article discusses a study which examined the impact of boosting T cell immunity on bird flu pandemic prevention. Killer T cells are described by the study's lead author Stephen Turner as the hit-man of the immune system. He and colleagues investigated how vaccine formulation could be...

  • Parenteral Influenza Vaccination Influences Mucosal and Systemic T Cell--Mediated Immunity in Healthy Adults. Guthrie, Terry; Christopher G. L. Hobbs; Davenport, Victoria; Horton, Rachel E.; Heyderman, Robert S.; Williams, Neil A. // Journal of Infectious Diseases;12/1/2004, Vol. 190 Issue 11, p1927 

    We sought to determine whether palatine tonsils (PTs) harbor naturally acquired influenza-specific T cell immunity and whether routine parenteral immunization with influenza vaccine influences mucosal and systemic T cell reactivity. We demonstrate that tonsillar and peripheral blood mononuclear...

  • ITS' Flunisyn Elicits Strong T-Cell Response in Phase IIa. Moran, Nuala // BioWorld Today;4/17/2013, Vol. 24 Issue 73, p2 

    The article reports that England-based Immune Targeting Systems Ltd. (ITS) has presented positive data on its universal influenza vaccine, Flunisyn in a Phase IIa trial. Results show that Flunisyn induces strong T-Cell responses in 95% of subjects in an elderly population, ages 65 to 74. A Phase...

  • Cell-mediated immune responses to influenza vaccination in healthy volunteers and allogeneic stem cell transplant recipients. Avetisyan, G.; Ragnavölgyi, E.; Toth, G. T.; Hassan, M.; Ljungman, P. // Bone Marrow Transplantation;Sep2005, Vol. 36 Issue 5, p411 

    Summary:Influenza is one of the most common respiratory diseases in humans. The response to vaccination is frequently poor in immunosuppressed individuals. The aim of the present study was to develop an enzyme-linked immunospot (ELISPOT) assay for measuring of the specific T-cell response to...

  • Characterization of pandemic influenza immune memory signature after vaccination or infection. Bonduelle, Olivia; Carrat, Fabrice; Luyt, Charles-Edouard; Leport, Catherine; Mosnier, Anne; Benhabiles, Nora; Krivine, Anne; Rozenberg, Flore; Yahia, Nora; Sarnri, Assia; Rousset, Dominique; van der Werf, Sylvie; Autran, Brigitte; Combadiere, Behazine // Journal of Clinical Investigation;Jul2014, Vol. 124 Issue 7, p3129 

    The magnitude, quality, and maintenance of immunological memory after infection or vaccination must be considered for future design of effective influenza vaccines. In 2009, the influenza pandemic produced disease that ranged from mild to severe, even fatal, illness in infected healthy adults...

  • From the Editor-in-Chief. Carson, Keith L. // BioProcessing Journal;Winter2014, Vol. 13 Issue 4, p5 

    An introduction is presented in which the editor discusses developments in the biotechnology sector, including the licensing of an adeno-associated viral vector, the licensed of an influenza vaccine produced with baculovirus technology, and T cell therapy.

  • A Prospective, Comparative Study of the Immune Response to Inactivated Influenza Vaccine in Pediatric Liver Transplant Recipients and Their Healthy Siblings. Madan, Rebecca Pellett; Tan, Maria; Fernandez-Sesma, Ana; Moran, Thomas M.; Emre, Sukru; Campbell, Andrew; Heroid, Betsy C. // Clinical Infectious Diseases;3/1/2008, Vol. 46 Issue 5, p712 

    Background. Annual influenza vaccination is routinely recommended for pediatric solid organ transplant recipients. However, there are limited data defining the immune response to the inactivated vaccine in this population. Methods. This prospective study compared the humoral and cell-mediated...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics